Data / Drug companies / Sacubitril and valsartan
Sacubitril and valsartan: 29 companies and 103 products in the FDA NDC directory
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sacubitril and valsartan is listed in the FDA National Drug Code Directory by 29 companies, with 103 products in commercial distribution. 93 of the products (90.3%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, film coated; tablet; pellet, and the newest product started marketing on October 26, 2026.
The request: Get every company that lists sacubitril and valsartan in the FDA NDC directory, with headquarters, website and number of employees. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 29
- Products
- 103
- Generic (ANDA) products
- 93 (90.3%)
- Application numbers
- 18
- Routes
- Oral
- Brand names
- Entresto
- openFDA record search
- api.fda.gov
Companies that list sacubitril and valsartan
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Aphena Pharma Solutions - Tennessee, LLC | 9 | tablet, film coated; tablet | Generic drugs (ANDA) | September 30, 2025 |
| Novartis Pharmaceuticals Corporation | 7 | tablet, film coated; pellet | New drug applications (NDA) | April 12, 2024 |
| AvKARE | 6 | tablet, film coated | Generic drugs (ANDA) | November 16, 2025 |
| Ascend Laboratories, LLC | 5 | tablet, film coated | Generic drugs (ANDA) | July 23, 2025 |
| Torrent Pharmaceuticals Limited | 5 | tablet | Generic drugs (ANDA) | July 16, 2025 |
| Novugen Pharma (USA) LLC | 4 | tablet, film coated | Generic drugs (ANDA) | July 16, 2025 |
| Alembic Pharmaceuticals Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | November 4, 2024 |
| Alembic Pharmaceuticals Limited | 3 | tablet, film coated | Generic drugs (ANDA) | November 4, 2024 |
| American Health Packaging | 3 | tablet, film coated | Generic drugs (ANDA) | June 11, 2026 |
| Amneal Pharmaceuticals NY LLC | 3 | tablet, film coated | Generic drugs (ANDA) | June 2, 2025 |
| Ani Pharmaceuticals, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | July 24, 2025 |
| Aurobindo Pharma Limited | 3 | tablet, film coated | Generic drugs (ANDA) | October 26, 2026 |
| AvPAK | 3 | tablet, film coated | Generic drugs (ANDA) | October 13, 2025 |
| Biocon Pharma Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | July 17, 2025 |
| Camber Pharmaceuticals, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | July 23, 2025 |
| Dr. Reddy's Laboratories Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | July 16, 2025 |
| Golden State Medical Supply, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | June 11, 2026 |
| Laurus Labs Limited | 3 | tablet, film coated | Generic drugs (ANDA) | November 11, 2024 |
| Lupin Pharmaceuticals, Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | July 29, 2025 |
| Macleods Pharmaceuticals Limited | 3 | tablet | Generic drugs (ANDA) | October 16, 2024 |
| Major Pharmaceuticals | 3 | tablet, film coated | Generic drugs (ANDA) | November 3, 2025 |
| NorthStar RxLLC | 3 | tablet, film coated | Generic drugs (ANDA) | June 29, 2026 |
| Novadoz Pharmaceuticals LLC | 3 | tablet, film coated | Generic drugs (ANDA) | July 16, 2025 |
| Somerset Therapeutics, LLC | 3 | tablet, film coated | Generic drugs (ANDA) | February 21, 2026 |
| Umedica Laboratories USA Inc. | 3 | tablet, film coated | Generic drugs (ANDA) | August 10, 2026 |
| XLCare Pharmaceuticals, Inc. | 3 | tablet | Generic drugs (ANDA) | September 30, 2025 |
| Zydus Lifesciences Limited | 3 | tablet | Generic drugs (ANDA) | July 8, 2025 |
| Zydus Pharmaceuticals USA Inc. | 3 | tablet | Generic drugs (ANDA) | July 8, 2025 |
| Coupler LLC | 1 | tablet, film coated | Generic drugs (ANDA) | December 16, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 81 | 78.6% |
| Tablet | 20 | 19.4% |
| Pellet | 2 | 1.9% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 93 | 90.3% |
| New drug applications (NDA) | 10 | 9.7% |
Pharmacologic classes
| Class | Products |
|---|---|
| Angiotensin 2 Receptor Blocker | 103 |
| Neprilysin Inhibitor | 103 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.